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2 
Abstract	31 
	32 
Background:	Multimodal	 enhanced	 recovery	 after	 surgery	 (ERAS)	 regimens	 have	33 
improved	outcomes	from	colorectal	surgery.		34 
Objective:	 We	 report	 the	 application	 of	 ERAS	 to	 patients	 undergoing	 radical	35 
cystectomy	(RC).	36 
Design,	 Setting	 and	 Participants:	 Prospective	 collection	 of	 outcomes	 from	37 
consecutive	patients	undergoing	RC	at	a	single	institution.	38 
Intervention:	Twenty-six	components	including	prehabilitation	exercise,	same	day	39 
admission,	 carbohydrate	 fluid	 loading,	 targeted	 intra-operative	 fluid	 resuscitation,	40 
regional	 local	 anesthesia,	 cessation	 of	 NG	 tubes,	 omitting	 oral	 bowel	 preparation,	41 
avoiding	drain	use,	early	mobilization,	chewing	gum	use	and	audit.	42 
Outcome	Measurements	and	Statistical	Analysis:	Primary	outcomes	were	length	43 
of	 stay	 and	 readmission	 rate.	 Secondary	 outcomes	 included	 intra-operative	 blood	44 
loss,	transfusion	rates,	survival	and	histopathological	findings.		45 
Results	 and	 Limitations:	 453	 consecutive	 patients	 underwent	 RC,	 including	 393	46 
(87%)	with	 ERAS.	 Length	 of	 stay	was	 shorter	with	 ERAS	 (median	 (IQR):	 8	 (6-13)	47 
days)	than	without	(18	(13-25),	p<0.001).	Patients	with	ERAS	had	lower	blood	loss	48 
(ERAS:	600	(383-969)	mls	vs.	1050	(900-1575)	mls	for	non-ERAS,		p<0.001),	lower	49 
transfusion	 rates	 (ERAS:	 8.1%	 vs.	 25%,	 Chi	 sq.	 p<0.001)	 and	 fewer	 readmissions	50 
(ERAS:	 15%	 vs.	 25%,	 Chi	 sq.	 p=0.04)	 than	 those	 without.	 Histopathological	51 
parameters	(e.g.	tumor	stage,	node	count	and	margin	state)	and	survival	outcomes	52 
did	not	differ	with	ERAS	use	 (all	p>0.1).	Multivariable	analysis	 revealed	ERAS	use	53 
was	(p=0.002)	independently	associated	with	length	of	stay.	54 
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Conclusions:	The	use	of	ERAS	pathways	was	associated	with	lower	intra-operative	55 
blood	 loss	and	faster	discharge	 for	patients	undergoing	RC.	These	changes	did	not	56 
increase	readmission	rates	or	alter	oncological	outcomes.		57 
Patient	summary:	Recovery	after	major	bladder	surgery	can	be	improved	by	using	58 
enhanced	 recovery	 pathways.	 Patients	 managed	 by	 these	 pathways	 have	 shorter	59 
length	of	stays,	lower	blood	loss	and	lower	transfusion	rates.	Their	adoption	should	60 
be	encouraged.	61 
	62 
  
4 
Introduction	63 
Radical	 cystectomy	 (RC)	 with	 pelvic	 lymph	 node	 dissection	 (PLND)	 is	 the	 gold	 standard	64 
treatment	 for	 muscle	 invasive	 BC	 [1],	 plays	 a	 key	 role	 in	 managing	 local	 failure	 after	65 
radiotherapy	 [2]	 and	 is	 an	 option	 for	 high	 risk	 local	 non-muscle	 invasive	 BC	 [3].	 RC	 is	 a	66 
morbid	procedure	that	often	performed	in	older	patients	with	co-existing	cardiopulmonary	67 
disease.	 Many	 patients	 develop	 post-operative	 complications,	 including	 13%	 (grade	 3-5)	68 
that	require	further	intervention	[4].	Consequently,	patients	who	could	benefit	from	RC	do	69 
not	always	receive	this	option	[5,	6].	Whilst	centralization	of	major	cancer	services	increases	70 
radical	treatments	and	subsequent	outcomes	[7],	the	morbidity	from	RC	still	limits	its	use.		71 
	72 
In	 colorectal	 surgery,	 the	 use	 of	 multimodal	 Enhanced	 Recovery	 after	 Surgery	 (ERAS)	73 
regimens	has	reduced	post-operative	morbidity	and	length	of	stay	[8,	9].	ERAS	introduces	a	74 
number	of	pre-,	peri-	and	post-operative	steps	to	improve	the	patient	pathway	[10].	Many	75 
ERAS	components	are	generic	 to	abdominal	surgery	and	so	have	been	 implemented	 in	RC	76 
without	 prospective	 evidence	 [11].	 However,	 RC	 includes	 surgery	 to	 the	 urinary	 and	77 
gastrointestinal	tracts	and	so	not	all	ERAS	components	may	be	suitable.		78 
	79 
There	have	been	several	reports	of	ERAS	in	RC	cohorts	[10-14]	and	one	RCT	[15].	This	RCT	80 
found	ERAS	improved	quality	of	life	and	reduced	morbidity	in	patients	undergoing	RC,	but	81 
did	 not	 shorten	 post-operative	 length	 of	 stay	 (LOS).	 Here	 we	 report	 the	 prospective	82 
adoption	of	ERAS	in	a	large	UK	centre,	where	the	opioid	receptor	antagonist	Alvimopan	[16]	83 
is	not	available	and	healthcare	design	does	not	incentivize	rapid	discharge.		84 
	85 
Materials	and	methods	86 
Patients	87 
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Consecutive	 patients	 undergoing	 RC	 and	 urinary	 reconstruction	 were	 enrolled	 in	 a	88 
prospective	 institutional	database.	From	February	2007	to	October	2016,	a	25	point	ERAS	89 
regimen	was	implemented.	The	regimen	(table	1)	was	derived	from	available	evidence	and	90 
practice	within	 colorectal	 surgery	[10].	Data	were	 collected	prospectively	and	all	patients	91 
undergoing	RC	were	 included	 in	 the	study.	The	use	of	ERAS	 reflected	 the	date	of	surgery.	92 
During	the	transition	period,	patients	were	identified	as	using	the	ERAS	pathway	if	they	had	93 
pre-operative	 carbohydrate	 loading,	 were	 allowed	 fluids	 until	 2	 hours	 prior	 to	 surgery,	94 
planned	 to	avoid	NGT,	used	a	 smaller	 incision	had	early	post-operative	mobilization	with	95 
diet	on	the	ward.	96 
	97 
ERAS	Protocol	98 
Pre-operative:	Counselling	in	the	outpatient	setting	was	performed	by	the	surgeon	(JWFC),	a	99 
cancer	nurse	specialist,	 an	anaesthetist	 (RG)	when	needed,	 and	a	 stoma	 therapist.	Typical	100 
consultations	 included	 wide	 ranging	 treatment	 discussions	 and	 lasted	 30-45	 minutes.	101 
Patients	were	advised	 to	maintain	a	normal	diet	until	 the	night	before	 surgery,	 to	 reduce	102 
cigarette	smoking	and	alcohol	intake,	and	were	given	an	information	booklet	regarding	their	103 
expected	 recovery.	 Increasing	 exercise	 activity	 (prehabilitation)	 was	 stressed	 as	 an	104 
important	 aspect	 of	 recovery	 and	 patients	 asked	 to	walk	 1	 hour	 per	 day	 (once	 or	 twice)	105 
between	 their	 initial	 consultation	 and	 surgery.	 Patients	 whose	 anaesthetic	 fitness	 was	106 
uncertain	were	reviewed	by	an	Anaesthetist	and	cardiopulmonary	exercise	(CPEX)	testing	107 
used	in	selective	cases.	Pre-morbidities	were	optimized	where	possible.	Anemia	was	treated	108 
with	 intravenous	 iron	 transfusion.	 Prior	 to	 surgery,	 patients	 attended	 clinic	 for	 stoma	109 
marking,	 to	 obtain	 6	 carbohydrate	 dinks	 (e.g.	 PreOp	 TM,	 Nutricia)	 and	 to	 collect	 a	 single	110 
injection	of	low	molecular	weight	heparin	(LMWH	e.g.	dalteparin	5,000	iu	s/c).	Patients	self-111 
administered	 dalteparin	 the	 evening	 before	 surgery	 and	 undertook	 carbohydrate	 fluid	112 
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loading	 for	 the	18	hours	prior	 to	 surgery.	Patients	were	allowed	oral	 fluids	up	 to	2	hours	113 
pre-operatively	and	food	6	hours	pre-operatively.		114 
	115 
Per-operative:	 At	 induction,	 a	 pre-planned	 anaesthetic	 protocol	was	 used	 (supplementary	116 
table	1).	Important	elements	included	limited	fluid	administration	targeted	to	losses,	the	use	117 
of	vasopressors	to	maintain	blood	pressures,	the	avoidance	of	nasogastric	tubes	(NGT)	and	118 
hypothermia	 (e.g.	 using	 Bair	 Hugger	 TM).	 Typically,	 only	 500-1000mls	 intravenous	119 
crystalloid	 was	 administered	 prior	 to	 bladder	 removal.	 Intra-operative	 steps	 taken	 to	120 
reduce	the	 impact	of	surgery	 included	the	use	of	small	 incisions	(typically	10cm)	or	robot	121 
assisted	laparoscopy,	the	use	of	vessel	sealers	(e.g.	LigasureTM	 impact),	clips	and	fastidious	122 
haemostasis.	Post-operative	analgesia	commenced	with	the	insertion	of	rectus	sheath	local	123 
anaesthetic	blocks	(usually	60mls	of	0.125%	bupivacaine)	and	tunnelled	cannulae	(lateral	124 
and	 superior	 to	 the	 incision	 prior	 to	wound	 closure)	 for	 a	 48	 hour	 bupivacaine	 infusion.	125 
Closure	was	performed	using	a	2/0	PDS	rectus	sheath	suture	and	4/0	monocryl	subcuticular	126 
skin	suture.	Antibiotic	prophylaxis	(1.2g	intravenous	co-amoxiclav)	was	administered	for	24	127 
hours	in	men	and	for	48	hours	in	women	(due	to	higher	contamination	from	vaginal	flora).	128 
DVT	prophylaxis	was	administered	from	6-12	hours	prior	to	surgery	and	for	at	least	28	days	129 
after	surgery	or	until	discharge	(whichever	was	longer).	130 
	131 
Radical	cystectomy:	In	males,	cystoprostatectomy	was	performed	in	an	antegrade	manner	to	132 
include	 the	 seminal	 vesicles.	 In	 females,	 anterior	 pelvic	 exenteration	 included	 the	 uterus,	133 
fallopian	 tubes	 and	 anterior	 vaginal	wall.	 Ovaries	were	 spared,	when	possible	 in	 younger	134 
women	 and	 in	 those	 with	 low	 stage	 disease.	 Lymphadenectomy	 was	 performed	 after	135 
bladder	removal	and	included	the	obturator,	internal	and	external	iliac	chains	to	the	level	of	136 
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the	 ureteric	 crossing	of	 the	mid	 common	 iliac	 vessels.	 Ureteroileal	 anastomosis	was	 by	 a	137 
Bricker	technique	and	the	Studer	technique	used	for	a	neobladder.		138 
	139 
Post-operative:	Management	was	undertaken	using	a	pre-specified	ERAS	regimen	(table	1).	140 
During	 the	 regimen’s	 introduction,	 an	 ERAS	nurse	 audited	 compliance.	On	 post-operative	141 
day	(POD)	#1	patients	were	allowed	chewing	gum,	one	clear	boiled	sweet/candy	per	hour	142 
and	30mls	 clear	non-fizzy	oral	 fluids	per	hour,	 as	 comfort	 allowed.	 Intake	was	 reduced	 in	143 
patients	feeling	nauseous	or	uncomfortable.	Patients	were	sat	out	of	bed	and	encouraged	to	144 
walk	10-20	meters.	Additional	analgesia	was	allowed	through	on	demand	patient	controlled	145 
analgesic	 (PCA)	 intravenous	 opiates.	 On	 POD#2	 patients	 aimed	 to	 walk	 100	meters	 and	146 
were	 allowed	 to	 drink	 clear	 fluids	 as	 tolerated.	 Nausea	 or	 vomiting	 were	 treated	 with	147 
reduced	 fluid	 intake	 and	 rest,	 rather	 than	 NGT.	 NGT	 were	 administered	 for	 repeated	148 
vomiting	with	epigastric	discomfort	or	in	the	presence	of	ileus/obstruction.	Light	diet	was	149 
introduced	when	the	patient	passed	flatus	or	had	a	bowel	movement.	Patients	without	flatus	150 
or	bowel	movement	on	POD#3,	had	a	glycerine	suppository	administered	per	rectum.	Total	151 
parenteral	nutrition	(TPN)	was	started	on	patients	not	tolerating	diet	by	POD#7,	or	sooner	152 
if	 post-operative	 complications	 were	 apparent.	 Abdominal	 and	 pelvic	 CT	 scan	 was	153 
undertaken	on	POD#5	 if	patients	were	not	progressing	according	 to	expectation	or	 in	 the	154 
presence	of	signs	of	 intra-abdominal	complications.	Discharge	occurred	when	the	patients	155 
were	comfortable,	self-caring	with	their	stoma,	mobile,	and	when	they	had	resumed	full	diet	156 
with	bowel	motion.		157 
	158 
Statistical	analysis	159 
Primary	 outcomes	 were	 LOS	 and	 post-discharge	 readmission	 rates.	 Secondary	 outcomes	160 
included	 intra-operative	 blood	 loss,	 intra-	 and	 post-operative	 blood	 transfusion	 rates,	161 
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operative	 duration,	 overall	 and	 bladder-cancer	 specific	 survival.	 For	 analysis,	 BMI	 was	162 
stratified	as	underweight	(BMI	<18.5),	healthy	(BMI	18.5–24.9),	overweight	(BMI	25–29.9)	163 
and	 obese	 (BMI	 ≥30)	 [17].	 Pre-operative	 anaemia	was	 defined	 as	 hemoglobin	 <12g/dl	 in	164 
both	sexes	and	renal	impairment	as	estimated	GFR	<40mls/min,	as	per	our	national	registry	165 
database.	Multivariable	analysis	 for	a	<7-day	LOS	was	performed	using	 logistic	regression	166 
with	factors	significant	from	univariable	analysis.	To	test	ERAS	through	any	learning	curve,	167 
cases	were	divided	into	quartiles	by	time,	and	variables	analysed	using	logistic	regression.	168 
	169 
Results	170 
Patients	and	recovery	components	171 
453	 consecutive	 patients	 underwent	 radical	 cystectomy	 (table	 2,	 figure	 1).	 The	 median	172 
(IQR)	age	was	70	years	(64-76)	and	14%	of	patients	were	³80	years	old.	Ninety-eight	were	173 
female	(22%)	and	50	(11%)	received	a	neobladder	reconstruction.	Around	one	quarter	of	174 
patients	 had	 renal	 impairment	 (eGFR	 <40mls/min	 in	 107	 (24%))	 prior	 to	 surgery,	 100	175 
(22%)	had	hydronephrosis	or	were	anephric,	the	median	(IQR)	BMI	was	29	(26.0-32.8)	and	176 
177	 (39%)	 had	 Charlson	 Comorbidity	 index	 (CCI)	 of	 4	 or	 higher.	 Twenty-eight	 patients	177 
underwent	robot	assisted	surgery,	of	which	25	had	intracorporeal	reconstruction.	Fifty-nine	178 
patients	 received	 neoadjuvant	 chemotherapy	 (NAC),	 18	 received	 adjuvant	 chemotherapy	179 
and	 29	 palliative	 chemotherapy.	 135	 patients	 had	 invasive	 cancer	 at	 TUR,	were	 younger	180 
than	80	years	of	age,	had	normal	renal	function	and	a	good	performance	status	(CCI	0-3)).	181 
As	such,	the	use	of	NAC	in	these	suitable	cases	was	57/135	(42%)	and	did	not	differ	by	ERAS	182 
use	 (42%	 vs.	 44%	 (non-ERAS)).	 Histological	 outcomes	were	 similar	 in	 patients	with	 and	183 
without	ERAS	recovery	(supplementary	table	2,	figures	2a	and	b).	In	particular,	the	lymph	184 
node	count	(mean	±	st.	dev:	10.7	±	4.7	for	ERAS	vs.	10.3	±	5.8	non-ERAS,	T	test	p=0.6)	and	185 
circumferential	margin	status	(positive	in	2.5%	(ERAS)	vs.	1.7%,	Chi	sq.	p=0.4)	were	similar.		186 
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	187 
ERAS	components	were	used	in	393	(87%)	patients	(figure	1a).	Direct	admission	from	home	188 
to	 surgery	 occurred	 in	 376	 (83%),	 rectus	 sheath	 local	 anaesthetic	 infusions	 used	 in	 241	189 
(53%),	 NGT	 avoided	 in	 382	 (84%),	 pre-operative	 oral	 bowel	 preparation	 avoided	 in	 390	190 
(86%)	and	drains	not	used	 in	20	 (4.4%)	patients.	Carbohydrate	 fluid	 loading	was	used	 in	191 
364	(80%)	and	drinking	until	2	hours	prior	to	anaesthesia	allowed	in	284	(63%).	Patients	192 
with	 ERAS	were	 older	 (median	 (IQR)	 71	 years	 (65-76))	 than	 those	without	 (60	 (61-70),	193 
Mann-Whitney	 U	 test	 p<0.001),	 more	 commonly	 female	 (23%	 vs.	 13%)	 and	 less	 often	194 
underwent	neobladder	reconstruction	(6.4%	vs.	42%),	but	otherwise	the	two	groups	were	195 
similar	(table	2).		196 
	197 
Length	of	stay	and	readmission	198 
Length	 of	 stay	 differed	 significantly	 for	 patients	with	 ERAS	 (median	 (IQR)	 8	 (6-13)	days)	199 
and	without	ERAS	 (18	 (13-25))	 recovery	 (supplementary	 figure	1	and	p<0.001).	Over	 the	200 
series,	 LOS	 reduced	 from	 a	 median	 of	 17	 days	 to	 6	 days	 (figure	 1b)	 and	 varied	 with	 a	201 
number	 of	 factors	 (table	 3).	 Longer	 stays	were	 seen	 in	 females	 (12	 days	 vs.	 9	 for	males,	202 
p=0.004),	with	neobladder	reconstruction	 (19	days	vs.	9	 for	 ileal	 conduit,	p=0.001),	 those	203 
with	an	abnormal	BMI	(p=0.001),	in	those	receiving	a	blood	transfusion	(14	days	vs.	10	for	204 
no	transfusion,	p=0.03)	and	in	those	with	comorbidities	(P=0.001)	(see	table	3	for	details).	205 
Shorter	 stays	were	 seen	with	 robot-assisted	 surgery	 (7	 days	 vs.	 10	 for	 open,	 p=0.03).	 In	206 
univariable	analysis	(table	3)	male	gender	(p<0.001),	ileal	conduit	diversion	(p<0.001),	low	207 
BMI	(p=0.01),	normal	renal	function	(p<0.001),	low	CCI	(p<0.001),	no	transfusion	(p=0.03),	208 
no	drain	(p=0.04)	and	all	components	of	the	ERAS	regimen	(p<0.001)	were	associated	with	209 
a	 LOS	 of	 <7days.	 Multivariable	 analysis	 revealed	 that	 female	 gender	 (logistic	 regression	210 
p<0.001),	neobladder	reconstruction	(p=0.02),	BMI	(p<0.001),	comorbidity	(CCI:	p<0.001)	211 
  
10 
and	 non-ERAS	 use	 (grouped	 into	 a	 single	 parameter,	 p=0.002)	 were	 independently	212 
associated	with	a	LOS	of	>7days.	In	only	neobladder	cases	(25	ERAS	and	25	non-ERAS),	sub-213 
group	analysis	revealed	that	ERAS	use	was	still	associated	with	shorter	LOS	(median	(IQR)	214 
15	(8-20)	(ERAS)	vs.	24	(18-28)	days	(non-ERAS),	Mann-Whitney	U	test	p<0.001).	215 
	216 
Readmission	 occurred	 in	 21%	 of	 patients	 (88/417	with	 readmission	 outcomes).	 Twenty-217 
two	patients	(25%)	stayed	1	day	and	24	(27%)	more	than	10	days.	Most	readmissions	were	218 
within	 30	 days	 of	 discharge	 (60/88	 (68%)).	 Patients	with	 ERAS	 had	 fewer	 readmissions	219 
(15%)	 than	 those	 without	 ERAS	 (25%,	 Chi	 sq.	 p=0.04).	 Readmission	 rates	 declined	 over	220 
time	 to	 11%	 for	 the	 last	 100	 cases	 (figure	 1d).	 We	 did	 not	 demonstrate	 differences	 in	221 
readmission	 length	 of	 stay	 by	 ERAS	 use	 (supplementary	 figure	 2).	 ERAS	 use	 was	222 
significantly	 associated	with	 shorter	 LOS	 and	 lower	 readmission	 rates,	 once	 adjusted	 for	223 
covariates	(including	learning	curve,	logistic	regression	p<0.05).	224 
	225 
Secondary	outcomes	226 
Intra-operative	 blood	 loss	 (median	 (IQR))	was	 lower	 for	 ERAS	 (600	 (383-969)	mls)	 than	227 
non-ERAS	(1050	(900-1575)	mls)	patients	(Mann-Whitney	U	test	p<0.001).	Consequently,	228 
transfusion	 rates	 were	 lower	 for	 ERAS	 (n=32	 (8.1%))	 than	 for	 non-ERAS	 (n=15	 (25%))	229 
patients	 (Chi	 sq	 p<0.001).	 Blood	 loss	 reduced	 across	 the	 series	 from	 an	 average	 of	 1,237	230 
(first	50	 cases)	 to	557mls	 (last	50	 cases,	 figure	1c).	The	median	 (IQR)	operative	duration	231 
was	 lower	 in	 the	 ERAS	 (2.9	 (2.5-4.0))	 vs	 non-ERAS	 (5.0	 (4.5-6.0))	 (Mann-Whitney	 U	 test	232 
p<0.001,	supplementary	 figure	2).	ERAS	use	was	significantly	associated	with	lower	blood	233 
loss	 (logistic	 regression	p<0.01),	but	not	 faster	operative	 times	 (p=0.5),	 once	adjusted	 for	234 
learning	curve.	235 
	236 
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Mortality	237 
At	median	(IQR)	follow	up	of	19	(8.3-37)	months,	335	(77%)	patients	were	alive	and	under	238 
surveillance	(17	missing).	There	were	77	deaths	(17%)	from	BC	(median	(IQR)	of	15	(7.2-239 
22)	months	 after	 surgery)	 and	24	 from	other	 causes	 (median	 (IQR)	19	 (6.1-34)	months).	240 
The	 30-day	 mortality	 rate	 was	 1.7%	 (1	 case)	 for	 non-ERAS	 and	 0.3%	 (1	 case)	 for	 ERAS	241 
patients	(Chi	sq.	p=0.14).	There	were	3	(5%)	deaths	 in	 the	non-ERAS	and	8	(2.1%)	 in	the	242 
ERAS	 cohort	 within	 90-day	 of	 cystectomy.	 Of	 the	 90-day	 deaths,	 8/11	 (73%)	 were	 from	243 
metastatic	 BC.	 In	 univariable	 and	 Multivariable	 analysis,	 neither	 30-day	 nor	 90-day	244 
mortality	rates	differed	with	ERAS	use	(Chi	Sq.	and	Logistic	regression	p>0.60).	There	was	245 
no	 difference	 in	 overall	 or	 bladder	 cancer	 specific	 survival	 when	 stratified	 by	 ERAS	 use	246 
(figure	2c	and	d).	247 
	248 
	249 
Discussion	250 
Since	introduction	into	colorectal	surgery,	enhanced	recovery	programs	have	improved	the	251 
outcomes	for	many	patients	undergoing	a	diverse	array	of	surgical	procedures	(reviewed	in	252 
[10]).	 The	 ERAS	 Society	 (www.erassociety.org)	 has	 protocols	 within	 several	 surgical	253 
specialities,	 including	 RC.	 Since	many	 RC	 patients	 develop	 complications	 during	 recovery	254 
[4],	 these	 patients	 may	 benefit	 more	 than	 most	 from	 refinements	 in	 post-operative	255 
management.	 Our	 data	 support	 the	 use	 of	 ERAS,	 demonstrate	 excellent	 improvements	 in	256 
post-operative	recovery	and	confirms	its	oncological	safety.	257 
	258 
There	has	been	one	prospective	RCT	of	ERAS	in	RC	patients	[15],	in	which	ERAS	use	led	to	259 
fewer	 complications,	 a	 faster	 improvement	 in	 return	 of	 quality	 of	 life,	more	 rapid	 bowel	260 
recovery	 and	 shorter	 stays	 in	 intermediate	 care,	 but	 no	 change	 in	 LOS.	 These	 findings	261 
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support	 and	 conflict	 with	 the	 field.	 For	 example,	 whilst	 others	 also	 found	 ERAS	 leads	 to	262 
accelerated	 bowel	 recovery	 and	 fewer	 complications,	 many	 report	 shorter	 hospital	 stays	263 
[11,	12,	18].	Within	the	USA,	Daneshmand	et	al.	reported	ERAS	using	110	patients	and	found	264 
its	use	reduced	median	LOS	to	4	days	[12].	With	the	UK,	Arumainayagam	et	al.	found	ERAS	265 
reduced	median	 LOS	 by	 around	4	 days	 [19].	LOS	 can	 reflect	 healthcare	 design	 as	well	 as	266 
rehabilitation.	In	the	UK,	patients	do	not	pay	for	healthcare	and	most	are	discharged	home.	267 
As	 such,	 there	 can	 be	 reluctance	 for	 rapid	 discharge.	 In	 the	 US,	 expensive	 hospital	 stays	268 
incentivise	 discharge	 home	 or	 to	 cheaper	 skilled	 nursing	 facilities	 (occurred	 in	 16%	269 
Daneshmand	et	al.	cohort).	Within	the	German	healthcare	setting,	reducing	the	LOS	is	not	an	270 
economic	pressure	and	so	may	not	have	changed	in	the	ERAS	population.	271 
	272 
Within	our	series,	ERAS	 improved	recovery,	accelerated	discharge	home	and	also	reduced	273 
the	burden	of	care	to	the	patient	and	their	medical/nursing	teams.	Faster	discharge	brings	274 
many	benefits,	including	more	rapid	access	to	adjuvant	chemotherapy	when	necessary.	Key	275 
elements	 to	 the	 success	 of	 ERAS	 involved	 staff,	 patients	 and	 infrastructure.	 Firstly,	 a	276 
multidisciplinary	 approach	 was	 vital.	 Surgical	 staff	 engaged	 with	 anaesthetic	 staff	 to	277 
plan/anticipate	patient	care,	nursing	staff	were	engaged	in	implementing	ERAS	on	the	ward	278 
and	auditing	pathway	compliance,	whilst	stoma/neobladder	reconstruction	nurses	attended	279 
clinics	 and	 the	ward	 to	 expedite	 competency.	 Unfit	 patients	 or	 those	 at	 increased	 risk	 of	280 
complications	 benefitted	 from	 additional	 surgeon/anaesthetist	 interaction.	 Secondly,	 pro-281 
active	 patient	 engagement	 was	 vital.	 This	 included	 explaining	 anticipated	 recovery	282 
timeframes,	 creating	 an	 ERAS	 booklet	 that	 patient’s	 read	 and	 completed	 during	 their	283 
recovery,	engaging	in	prehabilitation	exercise	regimens	for	the	patient	(and	involving	their	284 
next	of	kin	 in	 these	exercises),	 and	planning	discharge	before	admission	 (e.g.	 stocking	up	285 
with	 food	before	admission,	planning	 care	and	support	once	discharged).	With	regards	 to	286 
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infrastructure,	it	was	important	to	identify	the	pathway	as	new	and	different	to	traditional	287 
care.	This	helped	staff	feel	comfortable	with	rapid	changes	in	practice,	allowed	a	change	in	288 
patient	flow	(same	day	admission,	rapid	mobilisation	and	discharge),	and	justified	resource	289 
to	study	implementation	(auditing	pathway	compliance	during	introduction	was	very	useful	290 
for	the	less	experienced	medical	and	paramedical	staff).	291 
	292 
There	 are	 important	 limitations	 to	 our	 data.	 Firstly,	 the	 design	 precludes	 a	 meaningful	293 
Multivariable	 analysis	 of	 ERAS	 elements	 as	most	 components	 were	 used	 together	 rather	294 
than	 in	 different	 permutations.	 However,	 our	 analyses	 do	 reveal	 the	 importance	 of	 the	295 
patient	(e.g.	BMI	and	comorbidity),	which	makes	clinical	sense	and	matches	our	experience.	296 
Secondly,	these	data	are	derived	from	a	single	team	and	so	include	a	learning	curve.	Figure	1	297 
shows	that	the	rate	of	improvement	in	all	outcomes	slows	after	150	cases	and	changes	most	298 
rapidly	 around	 the	 implementation	 of	 ERAS.	 Improvements	 in	 these	 outcomes	 are	299 
associated	with	ERAS	use,	after	adjustment	for	learning	curve	and	other	covariates.	As	such,	300 
we	feel	key	drivers	for	change	include	both	a	learning	curve	and	ERAS	use.	Smaller,	shorter	301 
series	(and	so	less	impact	from	learning	curves)	support	our	belief	(e.g.	[12]	[19]).	Thirdly,	302 
the	 ERAS	 and	 non-ERAS	 cohort	 are	 imbalanced	 for	 reconstruction	 choice.	 This	 reflects	 a	303 
change	 in	practice	prompted	by	data	suggesting	QOL	 is	similar	 in	many	patients	with	 ileal	304 
conduit	and	neobladder	(unpublished	from	http://www.abdn.ac.uk/urology/research/otis/	305 
and	 [20])	 and	 the	 increased	 use	 of	 RC	 in	 older,	 less	 fit	 patients	 table	 2)	 once	 ERAS	306 
improvements	became	apparent.	We	believe	less	fit	patients	need	the	simplest,	least	morbid	307 
surgery	 with	 the	 fastest	 recovery.	 A	 direct	 comparison	 using	 only	 neobladder	 cases	308 
confirmed	that	ERAS	use	was	still	associated	with	shorter	LOS	and	faster	operations.	Overall	309 
our	rate	of	neobladder	use	is	similar	or	higher	than	the	UK	average	(for	example,	the	2009	310 
BAUS	complex	surgery	database	shows	5.7%	received	a	neobladder	in	the	UK).		311 
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	312 
Conclusion	313 
We	found	that	changes	to	the	RC	pathway	made	dramatic	improvements	to	patient	recovery	314 
without	affecting	oncological	outcomes.	In	particular,	enhanced	recovery	use	was	associated	315 
with	shorter	length	of	stay,	lower	blood	loss	and	transfusion	rates,	and	fewer	readmissions	316 
after	surgery.	317 
	318 
Take	home	messages	319 
Making	 the	 care	 of	 patient’s	 undergoing	 bladder	 removal	 simpler	 and	 more	 uniform	320 
improves	 their	outcomes.	 In	 particular,	 it	 can	 be	 associated	with	 shorter	 stays	 and	 fewer	321 
readmissions	after	discharge.	322 
	323 
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Figure	legends	394 
	395 
Figure	 1.	 The	 use	 of	 ERAS	 following	 radical	 cystectomy.	 ERAS	 Components	 and	396 
outcomes	are	aligned	for	the	453	consecutive	patients.	(a).	Individual	elements	from	the	26	397 
elements	 of	 ERAS	 are	 shown	 for	 each	 patient	 including	 robotic	 assisted	 surgery	 (RARC),	398 
omission	of	a	pelvic	drain,	the	use	of	oral	bowel	preparation,	same	day	admission	to	surgery,	399 
regional	 local	 anaesthesia	 (rectus	 sheath	 blockade),	 epidural	 use,	 nasogastric	 tube	 (NGT),	400 
small	 incision	 for	open	surgery,	pre-operative	 carbohydrate	 loading	and	designating	 their	401 
pathway	as	ERAS	to	facilitate	audit.	The	lower	line	indicates	the	extent	of	ERAS	compliance	402 
(shades	of	white	(6)	to	dark	grey	(10)	for	use	of	ERAS).	(b).	Length	of	stay	(days)	and	(c).	403 
blood	loss	(mls)	across	the	series	are	shown	as	median	and	interquartile	ranges	for	each	10	404 
consecutive	cases.	(d).	Readmission	rates	for	each	10	consecutive	cases	across	the	series.	405 
	406 
Figure	2.	Oncological	outcomes	stratified	by	the	use	of	ERAS.	Within	this	cohort	of	453	407 
patients,	there	was	no	difference	in	pathological	(a).	Lymph	node	count	or	(b).	Margin	status	408 
or	(c).	Overall	survival	or	(d).	Bladder	cancer	specific	survival)	outcomes	according	to	the	409 
use	of	ERAS.	410 
	411 
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Table	1.	Elements	of	the	ERAS	protocol	used	within	this	report.!
	
	
Domain Item Elements
Clinic 1.	Preoperative	counseling	and	education Advice	abour	maintaining	activity	levels
Dietary	and	alcohol	advice	
Details	of	admission	and	recovery
Written	material	detailing	post-op	recovery	plan
2.	Prehabilitation	exercise Walking	for	1	hour	per	day
3.	Preoperative	medical	optimization Optimization	of	co-morbidities
Smoking	cessation	advice
Plan	social	aspects	of	dicharge.	Who	will	help	care	for	patient?
4.	Correction	of	anemia Oral	Iron	supplements	or	I/V	Iron
Prior	to	admission 5.	Oral	mechanical	bowel	preparation Omitted.	Normal	diet	until	pre-op	fasting
6.	Self	administered	thromboprophylaxis Single	LMWH	injection	12	hours	prior	to	surgery	administerd	at	home
7.	Pre-operative	carbohydrate	loading Carbohydrate	loading	(6	cartons	of	drink	(e.g.	Nutricia	PreOp)	over	the	18	
hours	prior	to	surgery).	Careful	use	in	diabetic	patients
Admission 8.	Pre-operative	oral	intake Clear	fluid	until	2	hours	pre-op
Solid	foods	until	6	hours	pre-op
9.	Pre-anaesthesia	medication Avoidance	of	long-acting	sedatives
Anaesthesia 10.	Standard	anesthetic	protocol
11.	Anti-microbial	prophylaxis 24	hours	IV	Augmentin
12.	Skin	preparation Two	stage	preparation:	Spray	alcoholic	2%	chlorhexidine	gluconate	and	
paint	aqueous	10%	povidone-iodine
13.	Thromboembolic	prophylaxis Thromboembolic	compression	stockings
28	days	pharmacological	prophylaxis	with	LMWH	starting	day	before	
Intra-operative	pneumatic	compression	stockings
14.	Regional	analgesia Epidural	anaesthesia	omitted
Rectus	sheath	catheters	(0.125%	bupivicaine)	for	first	48	hrs
15.	Perioperative	fluid	management Avoid	overhydration.	Vasopressors	to	maintain	arterial	hypotension.	
Administer	<1l	crystalloid	until	bladder	removed.
16.	Nasogastric	intubation No	NGT	or	it	is	removed	at	the	end	of	surgery
17.	Preventing	intraoperative	hypothermia Use	of	a	warming	blanket	(Full	body	Bair	Hugger	TM	3M)
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Use	of	a	warming	blanket	(Full	body	Bair	Hugger	TM	3M)
Surgery 18.	Minimally	invasive	approach Mini-Open	Cystectomy	incision
RARC
19.	Resection	site	drainage Consider	omitting	pelvic	drain
20.	Urinary	drainage Ureteral	stents	or	transurethral	neo-bladder	catheter	should	be	used.	
Stents	removed	as	an	out	patient	at	10	days.	Catheter	removed	after	
cystogram	for	neobladder
21.	Wound	closure 2/0	polydioxanone	suture	(Ethicon)	to	rectus	sheath.	3/0	subcuticular	
Monocryl	(poliglecaprone)	suture	(Ethicon)	to	skin.
Post-operative 22.	Post-operative	diet Chewing	gum	to	start	at	4	hours	after	surgery
Oral	fluids	to	start	evening	of	surgery	-	30mls/hour	of	clear	non-fizzy	fluids
Resume	diet	when	passing	flatus,	mobile	and	pain	controlled.
23.	Prevention	of	PONV Anti-emetics	as	needed
Early	resumption	of	oral	fluids
24.	Postoperative	analgesia Rectus	sheath	catheters	(0.125%	bupivicaine)
Patient	controlled	opiate
I/V	Paracetamol/Acetaminophen	1g	qds	until	diet	resumed
25.	Early	mobilization 6	Hours	out	of	bed	on	POD	1
Walk	10-20m	on	POD	1
Walk	100m	on	POD	2
Walk	>100m	on	POD	3+
26.	Audit Audit	compliance.	Understand	problems.	Keep	resource	within	team
LMWH:	Low	molecular	weight	heparin
NGT:	Nasogastric	tube
POD:	Post-operative	day
PONV:	post-operative	nausea	and	vomiting	
iRARC:	Robot	assisted	Radical	Cystectomy	with	intra-corporeal	reconstruction
I/V:	Intravenous
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Table	2.	Details	of	the	patients	within	this	series.	
	
	 	
n % n %
Sex Male 303 77% 52 87%
Female 90 23% 8 13% 0.01
Age Median	(IQR) 71 65-76 66 60.8-70.3 <0.001
Age	>80 Yes 60 15% 2 3.3%
No 333 85% 58 97% 0.01
BMI Underweight	<18.5 2 0.5% 0 0.0%
Healthy	18.5-24.9 96 24% 18 30%
Overweight	25-29.9 105 27% 14 23%
Obese	>30 97 25% 13 22%
Missing 93 24% 15 25% 0.9
Pre-op	Hb	(g/dl) Median	(IQR) 131 120-142 129 118-136.5 0.6
Renal	Function Normal 285 73% 26 43%
eGFR	<40mls/min 102 26% 5 8.3%
Unknown 6 1.5% 29 48% 0.2
Upper	tracts Normal 294 75% 42 70%
Unilateral	hydronephrosis 70 18% 8 13%
Bilateral	hydronephrosis 17 4.3% 0 0.0%
Anephric/solitary 5 1.3% 0 0.0%
Unknown 7 1.8% 10 17% 0.4
Charlson	CI	score 0-3 201 51% 30 50%
4-5 117 30% 13 22%
6-7 16 4.1% 3 5.0%
>8 23 5.9% 5 8.3%
Unknown 36 9.2% 9 15% 0.6
Pre-op	BC	phenotype Low-risk	NMI 5 1.3% 1 1.7%
High-risk	NMI 165 42% 20 33%
Muscle	invasive	BC 223 57% 39 65% 0.4
Reconstruction Ileal	conduit 368 94% 35 58%
Neobladder 25 6.4% 25 42% <0.001
Abbreviations:	NMI	Non-muscle	invasive,	BC	Bladder	cancer,	Hb	hemoglobin
*	Statistical	tests:	Chi	square	for	categorical	&	Mann-Whitney	U	or	t-test	for	continuous	data.
ERAS Non-ERAS
p-value	*
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Table	3.	Factors	associated	with	length	of	stay	within	this	cohort.	
	
Element Number % Median OR p	value OR p	value
Age	(continous) Median	(IQR) 70	(64-76) 100% 10 6 15 0.98 0.95 1.0 0.2
Tumor	phenotype Low-risk	NMI 6 1.3% 7 6 17.5
High-risk	NMI 185 41% 10 7 16
Muscle	invasive	BC 262 58% 10 6 15 2.9 0.5 16.4 0.2
Sex Male 355 78% 9 6 15
Female 98 22% 12 7.8 16 2.2 1.3 3.7 <0.001 3.9 1.9 7.8 <0.001
Robot	assisted Yes 28 6.2% 7 6 10
No 425 94% 10 6 16 2.0 0.9 4.3 0.08
Reconstruction Ileal	conduit 403 89% 9 6 13
Neobladder 50 11% 19 12 25.3 6.4 2.5 16.4 <0.001 5.5 1.3 22.6 0.02
Body	Mass	Index	(continous) Median	(IQR) 29	(26-32) 76% 8 6 16 1.0 0.9 1.0 0.4
Hb	Pre-operation	(g/dl) Anemia 120 26% 7.5 6 14
Normal 175 39% 8 6 12
Missing 158 35% 13 8 19 0.9 0.6 1.5 0.7
Renal	Funtion Normal 311 69% 6 8 14
eGFR	<40mls/min 107 24% 11 7 15
Unknown 35 7.7% 15 12 19 2.1 1.3 3.3 <0.001 1.5 0.8 3.0 0.2
Hydronephrosis None 336 74% 10 6 15
Unilateral 78 17% 10 7 13.3
Bilateral 17 3.8% 12 7 15.5
Anephric/Solitary 5 1.1% 6 5 11.5
Unknown 17 3.8% 15 7.5 21.5 0.2 0.0 1.4 0.1
Charlson	CI 0-3 231 51% 7 6 12
4-5 130 29% 10 7 13
6-7 19 4.2% 12 7 19
>8 28 6.2% 26 22.3 31
Unknown 45 9.9% 15 12 17 32.4 4.3 242.5 <0.001 55.8 6.3 493.0 <0.001
IQR 95%	CI 95%	CI
Length	Of	stay	 Univariable* Multivariable	*
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Unknown 45 9.9% 15 12 17 32.4 4.3 242.5 <0.001 55.8 6.3 493.0 <0.001
Transfusion Yes 47 12% 14 8 21
No 406 88% 10 6 14 2.2 1.1 4.4 0.03 0.7 0.3 2.2 0.6
"ERAS	Pathway" Yes 393 87% 8 6 13
No 60 13% 18 13 25 45.5 6.2 331.3 <0.001 295 7.5 11649 0.002
Pre-Op	counselling Yes 288 64% 7 6 12
No 165 36% 13 9 20.5 5.8 3.6 9.5 <0.001
Prehabilitation	exercise Yes 239 53% 7 6 12
No 214 47% 12 8 19 3.9 2.6 5.9 <0.001
Mini-Incision Yes 374 83% 8 6 13
No 79 17% 16 12 24 5.3 2.6 10.6 <0.001
NGT	Tube Yes 71 16% 19 13 25
No 382 84% 8 6 13 13.2 4.7 36.8 <0.001
Rectus	sheath	LA No 212 47% 13 8 20
Yes 241 53% 7 6 12 3.8 2.5 5.7 <0.001
Same	day	Admission Yes 376 83% 8 6 13
No 77 17% 16 12.5 23 31.0 7.5 127.9 <0.001
Oral	bowel	preparation Yes 63 14% 16 13 24
No 390 86% 8 6 13 48.1 6.7 352.7 <0.001
Carbohydydrate	loading Yes 364 80% 8 6 12
No 89 20% 16 12 22 14.2 5.7 35.9 <0.001
Fasting	pre-op 2hrs	pre-op 284 63% 7 6 12
6hrs	pre-op 169 37% 13 9.0 20.5 4.9 3.1 7.8 <0.001
Drain Yes 433 96% 10 6.0 15.5
No 20 4.4% 7 5.3 11.5 2.6 1.0 6.4 0.04
Closure Mass	PDS	0 331 73% 11 7.0 17
Sheath	PDS	2/0 122 27% 7 6.0 12 3.0 1.9 4.9 <0.001
Oral	Fluids	from	day	1 Yes 403 89% 9 6.0 13
No 50 11% 19 14.0 25.3 11.3 3.5 37.0 <0.001
Chewing	gum/candy Yes 393 87% 8 6.0 13
No 60 13% 18 13.0 25 45.5 6.2 331.3 <0.001
*	Univariable:	Mann–Whitney	U	or	Kruskal–Wallis	tests.	Multivariable:	Logistic	regression	for	staying	±	7	days
Abbreviations:	Hb	Hemoglobin,	NMI	Non-muscle	invasive
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Supplementary	Figure	1
0
1
2
3
4
5
6
7
8
1 51 101 151 201 251 301 351 401
O
p
	d
u
ra
ti
o
n
	(
h
rs
)
1
10
100
1 51 101 151 201 251 301 351 401
R
e
a
d
m
is
si
o
n
	L
O
S
	(
d
a
y
s)
(a).
(b).
451
451
